Zymeworks (ZYME) announced that the FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-alpha, for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks to Highlight Pipeline and Asset Strategy at Key Investor Conferences
- Zymeworks Highlights New Ziihera Data to Broaden HER2 Cancer Reach
- Zymework’ partner Jazz to present on Ziihera at 2026 AACR Annual Meeting
- Zymeworks Highlights ADC and Novel Pan-RAS Platform Data Ahead of AACR Meeting
- Zymeworks price target raised to $48 from $33 at Evercore ISI